breviscapine dispersible tablets for poststroke sy

Product details:Drug name: breviscapine dispersible tablets Specifications: 0.15g*12pills*2plates Property: This product is light yellow pill,tasteless or slightly salty in taste. Conponents: breviscapine Functions: Activating blood circulation to relieve blood stasis,activating meridians to stop pains.The drug is suitable for the treatment of poststroke syndrome,coronary heart disease,angina pectoris. Indications: Coronary heart disease,angina pectoris,myocardial infarction,hyperviscosity,ischemic cerebrovascular disease(such as cerebral infarction,hemiplegia caused by sequela of cerebral hemorrhage), thrombotic disease,chronic hepatitis etc. Usage and Dosage: Oral administration,2 pills per time,3 times one day. Contraindication: The persons who are allergic to this product should be forbidden to take it. Adverse reaction: Uncertainty. Notes: 1.Individual patient will have a skin itching,but it will disappear automaticly after stopping taking the medication. 2.The patient should be forbidden to take it who have acute cerebral hemorrhage or bleeding tendency. Clinical test: The product is approvaled to have a biological effiency test by State Food and Drug Administration on January,2004,and 22 subjects were observed. Pharmaceutical action:Non-clinical pharmacodynamics tests result show that this product can reduce cerebral wet weight of rat with brain injury caused by cerebral artery local cerebral ischemia,cerebral water content, and reduce the rage of cerebral infarction.Furthermore,the product can prolong the survival time of mice with sodium nitrite poisoning significantly. Package: Aluminum foil for pharmaceutical packaging,PVC solid medicinal hard film. Validity: 2 years Storage: Air-proof,shading light. Excecutive standard: National Pharmaceutical Standard YBZ200862009 Document Number of Approval: National Pharmaceutical Approval NO.Z20090066